ProfileGDS5678 / 1421688_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 73% 75% 71% 74% 77% 78% 74% 74% 74% 74% 72% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9503375
GSM967853U87-EV human glioblastoma xenograft - Control 24.674673
GSM967854U87-EV human glioblastoma xenograft - Control 34.9090275
GSM967855U87-EV human glioblastoma xenograft - Control 44.5095871
GSM967856U87-EV human glioblastoma xenograft - Control 54.8605874
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1447877
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2076878
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8860474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8884574
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8864274
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.887574
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6401572
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8929975
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9796575